Ip Share Discussion Threads

[broadwood] 01/3/2016 07:15

While the major macroeconomic trends continue to cast significant uncertainty over the pace of the global economic recovery, which is likely to impact the general funding environment, the major global economies continue to increase expenditure on research and development to fuel growth.

IP Group remains well-positioned to respond to both this challenge and opportunity with a strong cash position and a healthy pipeline of opportunities across all of our sectors. Against this backdrop, we are cautiously optimistic about the prospects for the current year and beyond as we continue to grow and internationalise the Group

[backwoodsman] 14/2/2016 22:45

A GENE-SEQUENCING specialist that was spun out of Oxford University 11 years ago is preparing a £1bn float this year.

Oxford Nanopore Technologies will list in London, according to sources close to the company, ending speculation that it might follow other promising British science and technology developers on to New York’s Nasdaq exchange.

Bankers have yet to be appointed, but the management is believed to be eyeing a date in the final quarter of the year.

If the float comes off as planned, it will be seen as a victory for Britain’s ability to take bright scientific ideas and turn them into commercial enterprises. It will also mark big paydays for Oxford Nanopore’s founders and early-stage investors.

Among its biggest shareholders are IP Group — a listed fund that invests in Oxford start-ups — Lansdowne Partners, Odey Asset Management and Woodford Investment Management. Gordon Sanghera, the co-founder and chief executive, also has a stake. The company declined to comment.

Oxford Nanopore has developed a gene-sequencing — or DNA-on-a-chip — device the size of a memory stick, called the MinION. Strands of DNA pass through a minuscule hole in a cell’s membrane — a nanopore — and are then decoded using an electronic current.

The technology, though some way off receiving regulators’ approval for sale, has caused excitement because of its potential in helping identify targets for new medicines.

Since its launch in 2005, Oxford Nanopore has attracted £251m of funding. IP Group said last year that its 20% stake was worth £193m.

The company is not without its critics. Some analysts say its still unproven technology is overvalued. The most recent annual accounts showed a loss before tax of £41.7m. It did not make any revenue.

DNA analysis is an ultra-competitive market. The American giant Illumina was last week announced as a development partner for government-run Genomics England, in what some observers said was a snub for Oxford Nanopore. In 2006, Illumina snapped up rival Solexa, which began life at Cambridge University, in a $600m deal.

Pharmaceuticals and biotech companies have, in the past six months, been roiled by turmoil in world markets and concerns over the pricing of drugs in America.

Last week, however, saw signs of improvement. Shield Therapeutics, a Gateshead-based developer of treatments for kidney disease and anaemia, raised £32.5m by listing on AIM. Shield last year shelved its float plans because of market volatility.

[steptoe57] 14/2/2016 18:38

Kooba can't read the full article can u post here please

[eastbourne1982] 09/2/2016 22:59

In these markets I wouldn't be buying IP Group, I like the business however if the wider markets continue to fall this could easily go sub £1, sounds extreme however from experience this kind of business can completely tank in very poor market conditions.

[bamboo2] 09/2/2016 22:38

Starting to look more interesting now, hitting its target, which co-incides with some historical support.

Still at a premium to nav + cash though. Perhaps more so, given falls in constituents sp's.

[bamboo2] 19/1/2016 23:14

Eastbourne1982, this has traded at a strong premium for some years. Not fully sure why. Chart has confirmed a complex Head and Shoulders with a target at around 150. I have traded it a few times, not always successfully.

[eastbourne1982] 17/1/2016 16:08

I've been watching this one recently as I like the business however the valuation is a difficult one to call, given the state of the markets that NAV must have fallen hence the share price drop, one should expect to pay a premium though as the track record is decent, my issue is with the wider markets rather than IP Group itself, if the market irrationally tank these will collapse, on the flip side if the wider markets hold and recover this could be a decent risk / reward trade from around £1.75.

[bamboo2] 16/1/2016 17:08

Using the basic figures from the recent t/s £550m+£175m[cash]=£725m

divided by shares in issue, 564,648,168 = share price of approx £1.28

[bamboo2] 13/1/2016 22:18

SP still at a substantial premium.

[philo124] 12/1/2016 20:37

Buy and hold in SIPP and forget it.

[broadwood] 12/1/2016 13:51

IP Group said on Tuesday it expects 2015 to be its "most successful year" when it comes to financial performance.
The FTSE 250 intellectual property-based business developer posted a trading statement, ahead of its full year results due at the beginning of March.

It said the group had seen a number of significant deals in the second half of the year, including the admission of Diurnal Group plc to AIM in December which raised £30m.

Another three of IP Group's companies also announced significant fundraisings which totalled approximately £70m.

The company said the value of its portfolio is expected to be over £550m at 31 December 2015, up from £350m a year before.

It represents a net unrealised fair value increase of more than £85m during the year, excluding net investment.

The group also provided £76m of incubation, seed and development capital to its portfolio companies, up from £47m in 2014, as well as a further £40m strategic investment into Oxford Science Innovations.

The Group's gross cash and cash equivalents were in excess of £175m at the end of the year

[cwa1] 12/1/2016 09:45

Just seen this from this morning for the next to nothing that it is worth:-

12 Jan 16 IP Group PLC Numis Buy 199.40 358.00 358.00 Reiterates

[davr0s] 12/1/2016 09:32

Wouldn't say I was any more experienced but have held this on and off in recent years. It's a hard one as its struggled to push on price wise, so have ended up trading it a bit. It is on my watch list to buy sub200 so may add today on any dips. I am surprised it hasn't pushed on today as I though the update was very positive

[cwa1] 12/1/2016 08:07

Just glancing through this morning's news releases and this one seemed like one of the more upbeat and interesting ones. Wasn't familiar with it before but decided to take a small punt(at just under £2) prior to further investigations to see if a bigger stake is justified. Anyone know if there are any publicly available broker notes or research anywhere?

Also be grateful to know what more "experienced hands" thought of this morning's news.

Cheers for any input.

[broadwood] 12/1/2016 07:09

What's not to like.



The Group has seen significant activity within its portfolio during the second half of 2015, with a number of its portfolio companies announcing commercial developments and substantial fundraisings. The Group now expects 2015 to be its most successful year in terms of financial performance since its formation.

Significant transactions announced by portfolio companies in the second half of 2015 include the admission of Diurnal Group plc to AIM in December, raising GBP30m before expenses, and a further three of our quoted companies (Xeros Technology Group plc, hVIVO plc and Applied Graphene Materials plc) announcing significant fundraisings, totalling approximately GBP70m before expenses. Two of the Group's unquoted companies, First Light Fusion Limited and Ultrahaptics Limited, announced financings of GBP23m and GBP10m respectively.

The Directors now anticipate that the fair value of the Group's portfolio will be in excess of GBP550m at 31 December 2015, compared to GBP350m at 31 December 2014. This would represent a net unrealised fair value increase, excluding net investment, of more than GBP85m during the year (2014: GBP21m

[greek islander] 04/12/2015 12:07

As a relatively big shareholder in Xeros I have now bought in here - todays' 4.3% drop in price offered an excellent opportunity

[greek islander] 04/12/2015 12:06

As a relatively big shareholder in Xeros I have now bought in here - todays' 4.3% drop in price offered an excellent opportunity

[p1nkfish] 08/10/2015 22:27

mwg may need more funding - was in the top 10 of IPO by value and now a fraction.
some catalyst needed to get this back to and through 260'ish.

[philo124] 08/10/2015 20:16

Yep. Glad I took a bit off the table at 260p; looks more like a trading stock than a buy and hold in these market conditions.

[the oxford whale] 08/10/2015 18:19

Could be the news from Pacbio regarding their new instrument. I know illumina has taking a battering as well, and given IP group seems to trade almost entirely based on what nanopore is doing then it makes sense it would be down as well. Also biotech sector overall not doing too well recently either.

[pka3] 08/10/2015 12:15

wtf is happening ?

[davr0s] 08/10/2015 10:54

Glad I top sliced recently - seems to be dropping back as fast as it rose though on fairly low volume

[praipus] 28/9/2015 15:27

yes that is embarrassing....:)

[backwoodsman] 28/9/2015 12:59

Doesn't it look like IP have an interest in Cronin?